Skip to main content

Table 3 Changing of patient’s characteristics: comparison of values before and after dietary intervention

From: Placebo-controlled dietary intervention of stress-induced neurovegetative disorders with a specific amino acid composition: a pilot-study

 

Verum (n = 18)

Placebo (n = 14)

V vs. P

\( \overline{\mathrm{x}} \) ± SD

\( \overline{\mathrm{x}} \) ± SD

week 12

Baseline

Week 12 a

Diff

Baseline

Week 12 a

Diff

p b

Weight (kg)

83.4 ± 16.5

84.5 ± 17.1*

1.1 ± 1.7

81.7 ± 19.9

82.2 ± 19.5

0.4 ± 1.2

0.722

BMI (kg/m2)

28.0 ± 4.4

28.4 ± 4.6*

0.4 ± 0.5

28.8 ± 4.9

29.0 ± 4.7

0.2 ± 0.4

0.750

WC (cm) f

88 ± 11

89 ± 11

1 ± 2

83 ± 11

84 ± 12

1 ± 2

0.218

Female ≥ 88 cm (%n)+

7 (70%)

7 (70%)

0

2 (20%)

4 (40%)

2

0.123

WC (cm) m

100 ± 11

101 ± 11

1 ± 2

109 ± 11

108 ± 12

−1 ± 1

0.368

Male ≥ 102 cm (%n)+

4 (50%)

4 (50%)

0

3 (75%)

4 (100%)

1

0.279

BP systolic (mmHg)

135 ± 10

133 ± 13

−2 ± 11

130 ± 14

132 ± 17

2 ± 12

0.955

≥130 mmHg (%n)

14 (78%)

10 (56%)

−4

5 (36%)

10 (71%)

5

0.681

BP diastolic (mmHg)

85 ± 10

85 ± 9

0 ± 8

83 ± 8

84 ± 10

0 ± 10

0.512

Pulse pressure

51 ± 9

50 ± 7

−1 ± 11

46 ± 10

49 ± 11

3 ± 8

0.357

rHr (1/min)

69 ± 10

72 ± 9

3 ± 6

73 ± 10

72 ± 12

−1 ± 9

0.808

PNF

41 ± 5

33 ± 8*

−8 ± 9

39 ± 6

22 ± 9*

−17 ± 12

0.003

PN

16 ± 3

12 ± 4*

−3 ± 3

16 ± 3

10 ± 5*

−7 ± 5

0.168

Cortisol_m (ng/ml)c

7.5 ± 4.4

6.6 ± 4.1

−0.5 ± 3.6

6.0 ± 3.4

5.3 ± 3.4

−0.7 ± 3.4

0.425

Cortisol_e (ng/ml)c

1.2 ± 1.5

1.5 ± 1.6

0.6 ± 1.7

1.2 ± 1.2

0.9 ± 0.9

−0.3 ± 0.8

0.533

ΔCortisol (ng/ml)c

6.3 ± 5.0

5.6 ± 4.8

−0.6 ± 4.1

4.8 ± 3.9

4.4 ± 3.5

−0.4 ± 3.5

0.454

Serotonin (μg/l)c

171 ± 90

185 ± 100

5 ± 34

180 ± 50

190 ± 64

11 ± 30

0.356

CRP sensitive (mg/l)

2.9 ± 3.1

2.4 ± 2.6

−0.7 ± 2.9

7.1 ± 8.0

6.0 ± 7.8

−1.0 ± 2.5

0.120

GGT (U/l)

45 ± 48

58 ± 71*

13 ± 25

23 ± 11

24 ± 14

1.6 ± 4.8

0.180

TC (mg/dl)

219 ± 36

211 ± 40

−8 ± 22

217 ± 43

216 ± 36

−1 ± 20

0.561

HDL-C (mg/dl)

59 ± 27

59 ± 26

0 ± 6

62 ± 19

61 ± 14

−0.8 ± 9.3

0.301

LDL-C (mg/dl)

133 ± 34

125 ± 36

−8 ± 19

132 ± 44

132 ± 32

0 ± 21

0.561

LDL-C/HDL-C

2.6 ± 1.0

10.1 ± 32.9

−0.4 ± 0.8

2.3 ± 0.9

2.3 ± 1.0

0 ± 0.5

0.561

TG (mg/dl)

162 ± 88

153 ± 87

−9 ± 39

145 ± 61

136 ± 39

−10 ± 42

0.808

TG/HDL-C

3.4 ± 2.6

6.0 ± 11.9

2.6 ± 11.6

2.9 ± 2.0

2.5 ± 1.2

−0.4 ± 1.1

0.536

FPG (mg/dl)

99 ± 28

102 ± 44

3 ± 17

97 ± 17

92 ± 10

−5 ± 18

0.891

HbA1c (%)

5.8 ± 0.9

5.8 ± 0.9

0.1 ± 0,2

5.7 ± 0.3

5.7 ± 0.3

0 ± 0.3

0.750

HOMA-Index

3.2 ± 3.3

3.6 ± 3.7

0.4 ± 2.6

2.2 ± 1.2

2.5 ± 1.9

0.3 ± 1.8

0.488

Insulin-ECLIA (μU/ml)

11.9 ± 8.1

2.3 ± 1.0

−1.3 ± 6.1

8.8 ± 4.0

10.5 ± 7.5

1.8 ± 6.5

0.955

  1. abbreviations used: BP, blood pressure; BMI, body mass index; Cortisol: _m, morning; _e, evening; ΔCortisol, cortisol difference morning-evening; CRP sensitive, C-reactive protein sensitive; Diff, difference; ECLIA, Enhanced Chemiluminescent Immunoassay; FPG, fasting plasma glucose; GGT, gamma-glutamyltransferase; HbA1c, glycated haemoglobin A1c; HDL-C, HDL cholesterol; HOMA-Index, Homeostasis Model Assessment-Index; LDL-C, LDL cholesterol; PNF, Psychological Neurological Questionnaire; PN, psycho-neurovegetative stability; rHR, resting heart rate; TC, total cholesterol; TG, triglycerides; WC, waist circumference.
  2. p-value: aWilcoxon-test within groups, bMann–Whitney-U test: *p < 0.05.
  3. cdata not available for all patients (numbers listed in Additional file 2).
  4. +Verum: women n = 10, men n = 8; Placebo: women n = 10, men n = 4.